Omnicell, Inc. (OMCL)
| Market Cap | 5.58B |
| Revenue (ttm) | 892.21M |
| Net Income (ttm) | 32.19M |
| Shares Out | 42.58M |
| EPS (ttm) | 0.74 |
| PE Ratio | 174.86 |
| Forward PE | 37.59 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $129.40 |
| Previous Close | $126.90 |
| Change ($) | 2.50 |
| Change (%) | 1.97% |
| Day's Open | 128.72 |
| Day's Range | 127.51 - 130.74 |
| Day's Volume | 197,708 |
| 52-Week Range | 54.24 - 137.99 |
Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.
Omnicell, Inc. (OMCL) CEO Randall Lipps on Q4 2020 Results - Earnings Call Transcript
Shares of Omnicell (NASDAQ:OMCL) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 18.18% year over year to $0.91, which bea...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Reports Fiscal Year, Fourth Quarter 2020 Results Record 2020 Total Product Bookings of $1+ billion Full Year 2020 Revenues of $892.2 million
Omnicell (NASDAQ:OMCL) releases its next round of earnings this Monday, February 01. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.
3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--WVU Medicine Selects Omnicell One Intelligence Solution to Drive Better Pharmacy Inventory Management, Optimize Costs, Support Better Patient Care
Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.
Omnicell (OMCL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Preliminary Fiscal Year 2020 Financial Results
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell's EnlivenHealth™ Reports Strong Customer Demand for New SaaS Technology Solution to Help Pharmacies Meet COVID-19 Vaccination Challenges
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Partner with Guy's and St Thomas' NHS Foundation Trust, London on Development of European Technology-Enabled Intelligence Centre
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Owensboro Health to Deploy Omnicell's Technology-Enabled Services to Improve Safety and Efficiency in Medication Management
After a solid 2x rise since March lows of this year, at the current price of around $115 per share, Omnicell stock (NASDAQ: OMCL), a medication management services provider, has reached its ne...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Present at the J.P. Morgan 39th Annual Healthcare Conference
Omnicell (OMCL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Baxter International has approached medication management software vendor Omnicell with a takeover bid, Reuters reported, citing people familiar with the matter. Baxter's offer is in excess of...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Latest Advancements in Automation, Intelligence, and Technology-Enabled Services at Omnicell Illuminate 2020
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Allegheny Health Network Partners with Omnicell to Drive Safety and Efficiency for Medication Management Across Western Pennsylvania Network
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Present at Upcoming Investor Conferences
Omnicell, Inc. (OMCL) CEO Randall Lipps on Q3 2020 Results - Earnings Call Transcript
Omnicell (OMCL) delivered earnings and revenue surprises of 20.00% and 2.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Omnicell (NASDAQ:OMCL) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 21.05% year over year to $0.60, which b...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Reports Third Quarter 2020 Results
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Lehigh Valley Health Network Chooses Omnicell Solutions to Enhance Clinical and Operational Outcomes and Streamline Medication Management
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Memorial Hospital at Gulfport Selects Omnicell Central Pharmacy Dispensing Service to Enhance Medication Safety and Dispensing
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Launches EnlivenHealth™ to Aid Retail Pharmacies and Health Plans Improve Patient Adherence, Quality Measures, and Retention
NEW YORK--(BUSINESS WIRE)--Headline of release should read: Blue Wolf Capital Closes on Sale of Pharmaceutical Strategies Group’s 340B Business to Omnicell (instead of: Blue Wolf Capital Close...
NEW YORK--(BUSINESS WIRE)--Today, Blue Wolf Capital Partners (“Blue Wolf”), a New York-based private equity firm, announced the completion of the sale of Pharmaceutical Strategies Group’s 340B...
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2020 Earnings Results on October 27, 2020
The company hasn't yet set the price, interest rate, or other key terms for the securities.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Present at Upcoming Investor Conferences
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock?
Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.
Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Peninsula Regional Medical Center Extends Partnership with Omnicell to Enhance Safety and Efficiency in Sterile Compounding
In today’s article we look at recent news and updates for 3 stocks that my firm has an investment in. Again, I have a personal stake in these companies.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Acquire Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business
Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.
Omnicell, Inc. (OMCL) CEO Randall Lipps on Q2 2020 Results - Earnings Call Transcript
Omnicell (OMCL) delivered earnings and revenue surprises of -13.95% and 0.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Omnicell (NASDAQ:OMCL) rose 1.8% in after-market trading after the company reported Q2 results.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Reports Second Quarter 2020 Results
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell to Release Second Quarter 2020 Earnings Results on July 28, 2020
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Omnicell Streamlines Pharmacy Supply Chain Through New Cloud-Based Predictive Intelligence Solution, Omnicell One
About OMCL
Omnicell, together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies worldwide. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions ... [Read more...]
| Industry Health Information Services | IPO Date Aug 7, 2001 |
| CEO Randall Lipps | Employees 2,860 |
| Stock Exchange NASDAQ | Ticker Symbol OMCL |
Financial Performance
In 2020, Omnicell's revenue was $892.21 million, a decrease of -0.54% compared to the previous year's $897.03 million. Earnings were $32.19 million, a decrease of -47.51%.
Analyst Forecasts
According to 8 analysts, the average rating for Omnicell stock is "Buy." The 12-month stock price forecast is 137.00, which is an increase of 5.87% from the latest price.